Doxycycline for Lateral Epicondylalgia - RCT

Kaunas University of Medicine

Status: Unknown

Conditions: Lateral Epicondylalgia (Tennis Elbow)

Treatments: Drug: Placebo; Drug: Doxycycline

Study type: Interventional

Funder types: Other

Identifiers

NCT00631501

BE-2-47

Details and patient eligibility

About

Matrix metalloproteinases are involved in the pathogenesis of tendinopathy. Doxycycline, a widely available pharmaceutical agent mostly used for its antibiotic properties, also functions as an inhibitor of MMPs.

This study aims to investigate the effect of doxycycline treatment on lateral epicondylalgia (tennis elbow). During three weeks, patients receive doxycycline tablets 100 mg twice daily, or placebo. Main outcome variable is pain (VAS) at three weeks.

Serum and/or plasma levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases are measured.

Enrollment: 34 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-65
• Pain at the lateral side of the elbow ≥8 weeks
• Local tenderness on palpation of the lateral epicondyle
• Pain on resisted extension of the wrist

Exclusion criteria

• Rheumatic disorder
• History of fibromyalgia or generalised pain
• Elbow surgery (on the painful side)
• Active infection
• Glucocorticoid treatment during the duration of symtoms of epicondylalgia
• NSAID use within 1 w before presentation and during the study
• Pregnancy
• Taking drug that might interact with doxycycline

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

34 participants in 2 patient groups, including a placebo group

2

Placebo Comparator group

Treatment:

Drug: Placebo

Doxycycline

Experimental group

Description:

100 mg twice daily

Treatment:

Drug: Doxycycline